What is your profession?
MDNP DOOncology Nurse PhDNurse PA/PA-COther (please specify)

What Board Certifications do you have?
Med OncOncology Surgeon HematologistInternal Medicine Hem/OncFamily Practice Surgical OncOther (please specify) Radiation Onc

What is your primary specialty?
General OncologyHead, Neck, or Lung Cancers Gastrointestinal CancersGynecologic Cancer Genitourinary CancersHematological Malignancies Breast CancerOther

May we e-mail you for further clarification of your comments?
Yes No

How would you describe this course to your colleagues?

What in the program description did you find most compelling? Did your experience match your expectations?

Have you attended a prior Dana-Farber Master Class for Oncologists?
Yes No

If yes, how does this year’s program compare?

How does Dana-Farber Master Class compare to other CME programs you’ve attended?

Of the sessions currently in the course, which did you find MOST engaging? Please explain.

Which sessions did you find LEAST valuable? Please explain.

What activity or topic would you like to see in future Master Class courses? Please explain.

Please identify and provide feedback (knowledge, quality of presentation style, level of content) for each track you attended.

Please identify you how you will use information from each track in your clinical practice.

Select the tracks you attended


	Success You have claimed credit successfully. Print your certificate

October 26-27, 2018 New York, NY The Conrad Hotel

April 26-27, 2019 Los Angeles, CA The Intercontinental Hotel May 10-11, 2019 Chicago, IL The Swissotel October 25-26, 2019 New York, NY The Conrad Hotel

Agenda At-a-Glance*

* Please note the track order below does not reflect the individual agendas for each live course. Please see the live course locations tab for a detailed agenda.

Women's Cancers Track

Advances in Ovarian Cancer:
Evolving Therapeutic Choices for Newly Diagnosed and Recurrent Disease

HER2-Positive and Triple-Negative Breast Cancers: Current Treatment Paradigms and Emerging New Agents

Individualized Management of Hormone Receptor Positive Breast Cancer in the Adjuvant and Metastatic Settings

Panel Discussion
All Supportive Care and Women's Cancers Track Faculty

Supportive Care Track

Patient-Centered Approaches to Supportive and Palliative Care:
Commonly Encountered Symptoms and Scenarios

Cancer Survivorship: Meeting the Needs of a Growing Population

Genitourinary Cancers Track

Prostate Cancer:
Selection and Sequencing of Endocrine, Chemotherapeutic, Targeted, and Immunologic Approaches

Evidence-Based Management of Advanced Bladder and Renal Cancers

Panel Discussion
All Genitourinary Cancers Track Faculty

Head, Neck and Lung Cancers Track

Head and Neck and Thyroid Cancers:
Evidence-Based Approaches to Multimodal Management

Individualized Treatment Selection and Emerging Agents for Non-Small Cell and Small Cell Lung Cancer

Melanoma Cancer Track

Advanced Melanoma:
Best Practices for Treatment Selection and Overall Management in First and Later Line Settings

Panel Discussion
All Head, Neck and Lung Cancers and Melanoma Cancer Track Faculty

Sarcoma Track

New and Emerging Therapies for Soft Tissue Sarcoma and GIST: Recent Clinical Data and Expert Recommendations

Gastrointestinal Cancer Track

Esophagogastic and Pancreatic Cancers:
Current Multimodal Treatment of Localized Disease and Emerging Approaches to Metastatic Disease

Hereditary Gastrointestinal Cancers::
Best Practices for Screening, Diagnosis, Risk Assessment, and Management

Improving Outcomes from Colorectal Cancer: Diet, Lifestyle, and Chemoprevention

Colorectal Cancer:
Current and Emerging Strategies for Individualized Treatment Decisions in the Adjuvant and Metastatic Settings

Panel Discussion
All Gastrointestinal Cancers Track Faculty

Hematologic Malignancies Track

Non-Hodgkin and Hodgkin Lymphoma:
Risk Assessment and Treatment Selection in an Expanding Therapeutic Landscape

Myeloid Malignancies:
Incorporating Molecular Data and Novel Therapies into Current Practice Paradigms

Updates on Diagnosis, Prognosis, and Management of Myeloproliferative Neoplasms

Applying Recent Clinical Trial Data to Therapeutic Decision-Making in Multiple Myeloma

Chronic Lymphocytic Leukemia:
Current Best Practices for Management and Emerging Treatment Options

Practical Strategies for Preventing and Treating Venous Thromboembolism in the Patient with Cancer

Panel Discussion
All Hematologic Malignancies Track Faculty

Course Goal and Overview

The goal of this course is to assist oncologists with assessing and improving their skills in the diagnosis, treatment, and overall management of a wide range of common cancers.

This innovative, live two-day curriculum provides a comprehensive update of oncologic practice, including current best practices and updated guidelines, emerging clinical evidence, and recent expert opinion in nearly all major areas of practice. Highly interactive presentations are followed by lively discussion sessions, including both Q&A and panel discussion formats. Learners are encouraged to bring their most difficult cases and clinical questions, building clinical skills through exposure to practice and patient care standards set by the acknowledged master clinicians of DFCI.

Target Audience

This course is intended for Medical Oncologists seeking an in depth review of the latest treatment advances in oncology.

Acknowledgments

Amgen	Eisai Inc.	Millennium Pharmacuticals
Astellas	Genomic Health	Novartis
AstraZeneca	Genentech	Pfizer
Bayer HealthCare	Genzyme Corporation	Taiho Oncology
Bristol-Myers Squibb	Janssen Scientific Affairs	Tesaro
Celgene Corporation	Lilly USA

For questions or more information on our live courses or online activities, please contact:
Laurie Bertoncini, Program Manager
Phone: 610-361-9720 | Email: laurie@calibremeetings.com

This website uses cookies to ensure you get the best experience on our website. For more information on the cookies we use, please reference our Privacy Policy.

* Required
* First Name:
* Last Name:
Member ID:
* Phone Number:
* Email:
* Enter code:

* Message:

You have claimed credit successfully.